Results 201 to 210 of about 8,055 (251)

Beyond glycemic control: clinical cardiovascular effects of tirzepatide-a narrative review. [PDF]

Ther Adv Endocrinol Metab
Alawad AO, Merghani TH, Fadelelmoula TE, Elamin NA, Satti S, Edris AA, Hakim A, El-Hindi RF, Alhaj-Ali AA, Ibrahim WE, Mustafa MA, Sirelkhatim MM, Ahmed HH, Yousif NO.   +13 more
europepmc   +1 more source

Combination Pharmacotherapies for Obesity—Current Evidence and Future Directions

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
Combination pharmacotherapy for obesity can enhance weight loss by targeting complementary neuroendocrine and metabolic pathways. Such benefits are largely additive but limited by tolerability, cost and access. This review outlines practical clinical archetypes and a research agenda for safer, more precise and durable combination strategies across ...
A. B. M. Kamrul‐Hasan, Arnav Kalra, Nitin Kapoor, Deep Dutta, Kunal Mahajan, Robin Maskey, Syed Abbas Raza   +6 more
wiley   +1 more source

Tirzepatide Is Associated With Improved Metabolic Outcomes in People With Type 1 Diabetes and Overweight or Obesity: A Retrospective Cohort Study. [PDF]

Diabetes Obes Metab
Purcell AR, Longfield MSG, Rodrigo N, Glastras SJ.   +3 more
europepmc   +1 more source

Comparative Cardiovascular Outcomes of GLP‐1 Receptor Agonists Versus Bariatric Surgery: A Systematic Review and Network Meta‐Analysis

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
BS demonstrated more consistent and statistically significant reductions in all cardiovascular outcomes compared to GLP‐1RAs, which showed more variable efficacy, particularly for HF and MI. Nevertheless, GLP‐1RAs remain effective evidence‐based alternatives for cardiovascular risk reduction in patients who are not candidates for surgery.
Erfan Shirmohammadi, Negar Ghasemloo, Navid Ebrahimi, Narjes Mohammadzadeh, Amir Ehtemami, Mahan Babaei, Shakiba Fardoost   +6 more
wiley   +1 more source

Possible Attenuation of Early Weight Loss During Tirzepatide Therapy in a Patient Treated With Levosulpiride: A Case Report and Mechanistic Hypothesis. [PDF]

Cureus
Carducci A, Di Matteo P, Ferri C, Grassi D.   +3 more
europepmc   +1 more source

Efficacy and Safety of Tirzepatide Versus Dulaglutide in Type 2 Diabetes With or Without Established Atherosclerotic Cardiovascular Disease: A Network Meta‐Analysis of Randomized Clinical Trials

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
This network meta‐analysis of 4 randomized controlled trials (14,348 adults with type 2 diabetes, with or without established atherosclerotic cardiovascular disease) compared all clinically relevant doses of tirzepatide (1, 5, 10, 15 mg) against dulaglutide (0.75, 1.5, 4.5 mg).
Ahmed W. Hageen, Ahmed Farid Gadelmawla, Ahmad Omar Saleh, Salma Bahnasy, Safir Eladawi, Moatasem Abdelaziz, Khalil Iyad, Ahmed Hamdy Kandil, Karim Zinhom, Mohamed Reyad Mohamed, Hind Abdulhay, Mustafa Turkman, Basel Abdelazeem, Gregg C. Fonarow   +13 more
wiley   +1 more source

Preventative semaglutide and tirzepatide treatment does not alter disease progression in the 5xFAD mouse model of Alzheimer's disease. [PDF]

Cell Rep Med
Vear A, Olsen SA, Lange ECH, Müller MA, Svendsen C, Clemmensen C.   +5 more
europepmc   +1 more source

Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate‐Data Bayesian Longitudinal Meta‐Analysis

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
After discontinuation of semaglutide or tirzepatide, weight regain averaged 1.04 kg/month. Based on a linear model, half of treatment‐associated weight loss was projected to return by approximately 7.5 months and baseline weight by approximately 15 months, highlighting the need for early monitoring and maintenance planning.
Chia Siang Kow, Kaeshaelya Thiruchelvam, Dinesh Sangarran Ramachandram, Abdullah Faiz Zaihan   +3 more
wiley   +1 more source

Tirzepatide and the gut microbiota-obesity axis: metabolic mechanisms and therapeutic perspectives. [PDF]

Front Microbiol
Cadena-Ullauri S, Cadena Paredes AS, Guamán-Herrera L, Imbaquingo-Espinales J, Ruiz-Pozo VA, Tamayo-Trujillo R, Guevara-Ramírez P, Paz-Cruz E, Zambrano AK.   +8 more
europepmc   +1 more source

The Evolution of Medications for Obesity Management

JGH Open, Volume 10, Issue 9, September 2026.
ABSTRACT This narrative review provides an overview of progress in the development of obesity medications, including a synthesis of data describing the efficacy and safety of currently available agents and emerging therapeutic options. Historically, many obesity medications have been withdrawn from the market due to safety concerns.
Jaskirath Gill, Priya Sumithran
wiley   +1 more source